Study identifier:15994
ClinicalTrials.gov identifier:NCT03019549
EudraCT identifier:N/A
CTIS identifier:N/A
Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects
Healthy
Phase 1
Yes
Lanabecestat, Rosuvastatin
All
42
Interventional
18 Years - 65 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Oct 2019 by AstraZeneca
AstraZeneca
Eli Lilly and Company
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Rosuvastatin Period 1: 20 mg rosuvastatin administered once orally (PO) | Drug: Rosuvastatin Administered orally |
Experimental: Lanabecestat + Rosuvastatin Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8 | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 Drug: Rosuvastatin Administered orally |